HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.

Abstract
Although erythropoiesis-stimulating agents (ESAs) are effective at treating anemia, the association between hemoglobin (Hb) levels and survival is still unclear, especially for the incident Japanese hemodialysis (HD) population. The Japan Erythropoietin Treatment (JET) Study is an open multi-center, prospective, observational study designed to evaluate the relationship between the maintenance of Hb levels and new HD patient prognosis after the first administration of epoetin beta. Landmark analyses were performed to examine the relationship between Hb levels at 6 months and survival. Among a total of 10,310 patients, 6631 completed the initial 6 months of epoetin beta treatment (induction phase) and were followed up for a further 2.5 years (maintenance phase). Three-year survival rate of patients with <9 g/dL Hb levels after 6 months was 74.1%, which was significantly lower than 89.3% for patients with Hb levels 10 to 11 g/dL; the adjusted hazard ratio (HR) was 2.08 (95% CI, 1.57-2.77; P < 0.0001). Moreover, the 3-year survival rate for poor responders defined by Hb levels <10 g/dL and weekly epoetin beta doses ≥ 9000 IU during the induction phase was 71.6%, which was significantly lower than 89.4% for the group, which had Hb levels 10 to 11 g/dL excluding poor responders and those with excursion; the HR was 1.71 (95% CI, 1.13-2.60; P = 0.0118). Adverse events related to the treatment were reported in 71 of 10,310 patients (0.69%). These findings suggest that the achieved low Hb levels and poor response to ESA therapy are significantly associated with high mortality.
AuthorsTadao Akizawa, Akira Saito, Fumitake Gejyo, Masashi Suzuki, Yoshiki Nishizawa, Yasuhiko Tomino, Yoshiharu Tsubakihara, Takashi Akiba, Hideki Hirakata, Yuzo Watanabe, Hideki Kawanishi, Masami Bessho, Yukio Udagawa, Kotonari Aoki, Yukari Uemura, Yasuo Ohashi, JET Study Group
JournalTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 18 Issue 5 Pg. 404-13 (Oct 2014) ISSN: 1744-9987 [Electronic] Australia
PMID24571446 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.
Chemical References
  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • epoetin beta
  • Erythropoietin
Topics
  • Aged
  • Anemia (drug therapy, etiology)
  • Erythropoietin (adverse effects, therapeutic use)
  • Female
  • Follow-Up Studies
  • Hematinics (adverse effects, therapeutic use)
  • Hemoglobins (metabolism)
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Recombinant Proteins (adverse effects, therapeutic use)
  • Renal Dialysis (methods)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: